Device Trial Radar · NCT07626658
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
471
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
May 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- IMDEA FoodAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abbott Laboratories (Pak) Ltd.
- First posted
- Jun 4, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to improve how we understand and manage blood sugar responses in adults without diabetes. Even in people who appear healthy, blood sugar levels after meals can behave in different ways. These patterns may help predict future risk of diseases such as type 2 diabetes or other cardiometabolic problems. To study this, researchers at IMDEA Nutrition have developed a computer algorithm called GLIA, which uses artificial intelligence (AI) to analyze continuous glucose monitoring (CGM) data. The goal is to classify people into different "glucotypes", meaning typical patterns of how their blood sugar behaves throughout the day. These glucotypes could help tailor dietary recommendations in the future. Goals of the study 1. Train and validate the GLIA algorithm\*\* in a large and diverse sample of adults. 2. Study how glucotypes relate to health indicators\*\*, such as blood pressure, body composition, cholesterol, or lifestyle. 3. Predict how each person responds to different foods\*\*, to support personalized nutrition advice. Who can participate? Adults 18-70 years old who: * Do not\*have diagnosed diabetes or serious metabolic disease. * Agree to wear a glucose sensor for 14 days. * Can keep stable eating habits and record diet and physical activity. What participation involves The study lasts 3 weeks and includes 3 visits: Visit 1 - Screening (20 min): * Review of eligibility criteria. * Explanation of the study. * Signing informed consent. * Visit 2 - Initial assessment (45 min) * Collection of personal and health information. * Measurements: weight, height, waist, body composition, blood pressure. * Placement of a FreeStyle Libre 3 CGM sensor. * Instructions for: * Completing two 3-day food records (one each week). * Taking photos of all meals. * Reporting physical activity. Continuous monitoring (14 days) Visit 3 - Final evaluation (45 min) * Review of diet records. * Repeat measurements. * Blood and urine samples are collected for metabolic and molecular analyses. Meal photos are analyzed using an AI-based food recognition model. The system identifies foods and estimates nutrients (macronutrients, vitamins, minerals, glycemic index, etc.). This helps researchers understand how meals relate to blood sugar patterns. Potential benefits: Although participants may not receive direct health benefits, the study will: * Improve understanding of how healthy people process glucose. * Help identify early risk markers for metabolic diseases. * Contribute to developing \*\*personalized nutrition tools\*\* based on individual glucose responses. Risks: are minimal and mainly include: * Mild skin irritation from the CGM sensor. * Temporary discomfort from blood draw.
Conditions
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
- Artificial Intelligence Mobile Application
Interventions
Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor)Device
The intervention consists of applying and wearing a 14-day continuous glucose monitoring (CGM) device that captures interstitial glucose every minute under free-living conditions. This wearable flash sensor is used exclusively for passive data collection; it does not provide insulin delivery, therapeutic adjustments, or real-time clinical management. What distinguishes this intervention is its integration into a multimodal data-capture system: participants simultaneously complete structured dietary records, submit standardized meal photographs for AI-based food recognition, and undergo detailed phenotyping. The CGM data are then processed through the study's proprietary GLIA algorithm to derive individualized glucose-response patterns ("glucotypes"). This combination of high-frequency glucose monitoring, dietary image analytics, and machine-learning modeling differentiates the device's use from typical clinical or self-management applications in other studies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glucotype Classification Derived From Continuous Glucose Monitoring DataTime frame: Assessed continuously over 14 days of CGM wear, with glucotype classification calculated after completion of the full 14-day glucose-monitoring period for each participant.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IMDEA Nutrition
Madrid, Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.